Mankind Pharma's Q2 FY 2026-27 Quarterly Results

Result Summary

• Mankind Pharma Ltd reported a 8.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 17.0%.
• Its expenses for the quarter were up by 6.0% QoQ and 10.7% YoY.
• The net profit increased 24.7% QoQ and increased 37.7% YoY.
• The earnings per share (EPS) of Mankind Pharma Ltd stood at 17.2 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Mankind Pharma Ltd is a prominent pharmaceutical company known for its wide range of healthcare products, including pharmaceuticals, over-the-counter medications, and wellness products. The company operates in the competitive pharmaceutical industry and has been expanding its reach in both domestic and international markets. While specific recent major developments are not provided, Mankind Pharma has historically focused on innovation and expanding its product portfolio to meet the growing demands of healthcare. The company's commitment to quality and affordability has been a significant driver of its business strategy.

Revenue

In the second quarter of the fiscal year 2027 (Q2FY27), Mankind Pharma Ltd reported a total income of ₹4,432.71 crores. This reflects an increase of 8.8% from the previous quarter (₹4,075.59 crores in Q1FY27) and a substantial year-over-year growth of 17.0% compared to Q2FY26 (₹3,789.03 crores). The consistent growth in total income indicates robust revenue generation over the comparative periods. This upward trend highlights the company's effective strategies in revenue management and market penetration.

Profitability

For Q2FY27, the company achieved a Profit Before Tax (PBT) of ₹925.43 crores, which marks a significant quarter-over-quarter increase of 20.9% from ₹765.51 crores in Q1FY27. Compared to Q2FY26, there is a remarkable year-over-year growth of 48.9% from ₹621.70 crores. After accounting for taxes, the Profit After Tax (PAT) for Q2FY27 stands at ₹716.12 crores, up by 24.7% from the previous quarter and 37.7% year-over-year. This growth in profitability is accompanied by an increase in Earnings Per Share (EPS) to ₹17.20, representing a 25.2% rise from Q1FY27 and a 38.9% increase from Q2FY26. These figures demonstrate the company's ability to enhance its profitability efficiently over the quarters.

Operating Metrics

Mankind Pharma Ltd's total expenses for Q2FY27 amounted to ₹3,507.28 crores, reflecting a 6.0% increase from Q1FY27 and a 10.7% rise from Q2FY26. The growth in expenses is relatively moderate compared to the increase in total income, indicating controlled cost management. The tax expense for the quarter was ₹212.99 crores, showing a 9.0% increase quarter-over-quarter and a 105.1% year-over-year increase. The substantial rise in tax expenses aligns with the growth in profitability, reflecting the company's higher taxable income. These operating metrics suggest effective management of operational costs and tax obligations in line with revenue growth.